Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients

Expert Opinion on Biological Therapy

Volumn 14, Issue 2, 2014, Pages 145-150

  Borrás Blasco, Joaquín ^a   Gracia Pérez, Antonio ^a   Rosique Robles, J Dolores ^a   Casterá, Md Elvira ^a   Abad, F Javier ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

Author keywords

Ankylosing spondylitis; Dosing; Etanercept; Psoriatic arthritis; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST CONTROL; DRUG COST; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UVEITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPAIN; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84891907595     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.868433     Document Type: Article

References (21)

1. Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res 2011;63:373-82
2. Johnson CJ, Reilly KM, Murray KM. Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother 2001;35:464-71
3. Klareskog L, Gaubitz M, Rodŕiguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47
4. Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 2013;15:R67
5. Kobelt G, Lekander I, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011;27:193-200
6. Raffeiner B, Botsios C, Sfriso P, et al. The effects of low dose etanercept on disease control and radiographic progression in moderate to severe rheumatoid arthritis. Arthritis Rheum 2010;62:S120
7. Cantini F, Niccoli L, Cassarà E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biologics 2013;7:1-6
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
9. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8
10. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86
11. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
12. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
13. Berthelot JM, Varin S, Cormier G, et al. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine 2007;74:144-7
14. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-16
15. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 2013;381:918-29
16. Botsios C, Furlan A, Otsuni P, et al. Effects of low-dose etanercept in maintaining das-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Ann Rheum Dis 2009;66(Suppl II):54
17. Navarro-Compan V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011;30:993-6
18. De Stefano R, Frati E, De Quattro D, et al. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 2013. [Epub ahead of print]
19. Inciarte-Mundo J, Hernández MV, Rosario V, et al. Reduction of biological agent dose in rheumatic diseases: Descriptive analysis of 153 patients in clinical practice conditions. Reumatol Clin 2013. [Epub ahead of print]
20. Navarro-Compán V, Moreira Navarrete V, Ariza Ariza R, et al. Costes farmacológicos asociados al ajuste de dosis de etanercept en pacientes con espondilitis anquilosante en remisión. 56 Congreso SEFH; 2011
21. Rubio-Terrés C, Ordovás Baines JP, Pla Poblador R, et al. Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp 2007;31:78-92